Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 8 / Drugs : 9 - (DrugBank : 2) / Drug target genes : 2 - Drug target pathways : 3

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Blinded cdca 250 MG TID
   Mirum Pharmaceuticals, Inc.
      2020   Phase 3   NCT04270682   Brazil;United States
Blood tests
   Sheba Medical Center
      2010   -   NCT01613898   Israel
Cdca weight-based dose TID
   Mirum Pharmaceuticals, Inc.
      2020   Phase 3   NCT04270682   Brazil;United States
Chenodeoxycholic acid
   Department of Veterans Affairs
      1999   -   NCT00018694   United States
   Fujimoto Pharmaceutical Corporation
      2020   Phase 3   JPRN-jRCT2080225062   Japan
   Leadiant Biosciences, Inc.
      2024   Phase 3   NCT06260748   Israel
   National Center for Research Resources (NCRR)
      1996   Phase 2   NCT00004346   United States
Chenodeoxycholic acid leadiant
   Humanis Saglik Anonim Sirketi
      2022   Phase 1   NCT06180057   Jordan
Lovastatin
   National Center for Research Resources (NCRR)
      1996   Phase 2   NCT00004346   United States
Mutation analysis
   TRPHARM
      2019   -   NCT04218006   Turkey
OPEN-label cdca 250 MG TID
   Mirum Pharmaceuticals, Inc.
      2020   Phase 3   NCT04270682   Brazil;United States
Rescue medication cdca 250 MG TID
   Mirum Pharmaceuticals, Inc.
      2020   Phase 3   NCT04270682   Brazil;United States